Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis

British Journal of Clinical Pharmacology

Volumn 80, Issue 2, 2015, Pages 209-220

  Ruxton, Kimberley ^a   Woodman, Richard J ^a   Mangoni, Arduino A ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

all cause mortality; cognitive impairment; drugs with anticholinergic effects; falls; older adults; risk scoring systems

Indexed keywords

AMITRIPTYLINE; OLANZAPINE; PAROXETINE; RISPERIDONE; TRAZODONE; CHOLINERGIC RECEPTOR BLOCKING AGENT;

AGED; ANTICHOLINERGIC EFFECT; ARTICLE; CASE CONTROL STUDY; COGNITIVE DEFECT; COHORT ANALYSIS; FALLING; GERIATRIC PATIENT; HUMAN; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CHEMICALLY INDUCED; FEMALE; MALE; STATISTICAL BIAS; VERY ELDERLY;

ACCIDENTAL FALLS; AGED; AGED, 80 AND OVER; BIAS (EPIDEMIOLOGY); CHOLINERGIC ANTAGONISTS; COGNITION DISORDERS; FEMALE; HUMANS; MALE;

EID: 84937521738     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12617     Document Type: Article

References (59)

1. Bostock CV, Soiza RL, Mangoni AA,. Association between prescribing of antimuscarinic drugs and antimuscarinic adverse effects in older people. Expert Rev Clin Pharmacol 2010; 3: 441-52.
2. Brown JH, Laiken N,. Muscarinic receptor agonists and antagonists. In: Goodman and Gilman's the Pharmacological Basis of Therapeutics, 12th edn. NY, USA: McGraw Hill, 2011: 219-37.
3. Mintzer J, Burns A,. Anticholinergic side-effects of drugs in elderly people. J R Soc Med 2000; 93: 457-62.
4. Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G,. Cholinergic transmission. In: Rang and Dale's Pharmacology, 7th edn. Edinburgh, UK: Churchill Livingstone, 2012: 151-73.
5. Picciotto M, Alrega M, Jentsch D,. Acetylcholine. In: Neuropsychopharmacology: The Fifth Generation of Progress, eds Davis KL, Charney D, Coyle JT, Nemeroff C. Philadelphia, USA: Lippincott Williams and Wilkins, 2002: 1-14.
6. van Waarde A, Ramakrishnan NK, Rybczynska AA, Elsinga PH, Ishiwata K, Nijholt IM, Luiten PGM, Dierckx RA,. The cholinergic system, sigma-1 receptors and cognition. Behav Brain Res 2011; 221: 543-54.
7. Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K,. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. Br Med J 2006; 332: 455-9.
8. Cao YJ, Mager DE, Simonsick EM, Hilmer SN, Ling SM, Windham BG, Crentsil V, Yasar S, Fried LP, Abernethy DR,. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther 2008; 83: 422-9.
9. Hilmer SN, Mager DE, Simonsick EM, Ling SM, Windham BG, Harris TB, Shorr RI, Bauer DC, Abernethy DR,. Drug burden index score and functional decline in older people. Am J Med 2009; 122: 1142-49.
10. Staskin DR, Zoltan E,. Anticholinergics and central nervous system effects: are we confused? Rev Urol 2007; 9: 191-6.
11. Somers M, Rose E, Simmonds D, Whitelaw C, Calver J, Beer C,. Quality use of medicines in residential aged care. Aust Fam Physician 2010; 39: 413-6.
12. Sarter M, Albin RL, Kucinski A, Lustig C,. Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function. Exp Neurol 2014; 257c: 120-29.
13. Ziere G, Dieleman JP, Hofman A, Pols HAP, Van Der Cammen TJM, Stricker BHC,. Polypharmacy and falls in the middle age and elderly population. Br J Clin Pharmacol 2006; 61: 218-23.
14. Han L, McCusker J, Cole M, Abrahamowicz M, Primeau F, Elie M,. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med 2001; 161: 1099-105.
15. Boustani M, Campbell N, Munger S, Maidment I, Fox C,. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health 2008; 4: 311-20.
16. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR,. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol 2006; 46: 1481-6.
17. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE,. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008; 168: 508-13.
18. Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, Harris TB, Hanlon JT, Rubin SM, Shorr RI, Bauer DC, Abernethy DR,. A drug burden index to define the functional burden of medications in older people. Arch Intern Med 2007; 167: 781-7.
19. El-Fakahany E, Richelson E,. Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol 1983; 78: 97-102.
20. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A,. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002; 303: 791-804.
21. Sladek RM, Tieman J, Currow DC,. Searchers be aware: limiting PubMed searches to 'humans' loses more than you think. Intern Med J 2010; 40: 88-9.
22. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JAC,. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Br Med J 2011; 343: d5928.
23. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P,. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses, 2008. Available at http://www.ohri.ca/programs/clinical-epidemiology/oxford.htm (last accessed 26 March 2015)
24. Lowry E, Woodman RJ, Soiza RL, Mangoni AA,. Associations Between the Anticholinergic Risk Scale Score and Physical Function: Potential Implications for Adverse Outcomes in Older Hospitalized Patients. J Am Med Dir Assoc 2011; 12: 565-72.
25. Lowry E, Woodman RJ, Soiza RL, Hilmer SN, Mangoni AA,. Drug Burden Index, Physical Function, and Adverse Outcomes in Older Hospitalized Patients. J Clin Pharmacol 2012; 52: 1584-91.
26. Lackner TE, Wyman JF, McCarthy TC, Monigold M, Davey C,. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc 2008; 56: 862-70.
27. Campbell NL, Boustani MA, Lane KA, Gao S, Hendrie H, Khan BA, Murrell JR, Unverzagt FW, Hake A, Smith-Gamble V, Hall K,. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology 2010; 75: 152-59.
28. Marras C, Gruneir A, Wang X, Fischer H, Gill SS, Herrmann N, Anderson GM, Hyson C, Rochon PA,. Antipsychotics and mortality in parkinsonism. Am J Geriatric Psych 2012; 20: 149-58.
29. Trifiro G, Verhamme KMC, Ziere G, Caputi AP, Stricker BHC, Sturkenboom MCJM,. All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiol Drug Saf 2007; 16: 538-44.
30. Hoffmann VP, Kennedy JS, Young CA, Feldman PD, Deberdt W,. A placebo-controlled 10-week prospective comparison of the occurrence of falls in dementia: olanzapine versus risperidone. In: International Psychogeriatrics, 2003: 265-66.
31. Berdot S, Bertrand M, Dartigues JF, Fourrier A, Tavernier B, Ritchie K, Alperovitch A,. Inappropriate medication use and risk of falls-a prospective study in a large community-dwelling elderly cohort. BMC Geriatr 2009; 9: 30.
32. Coupland CAC, Dhiman P, Barton G, Morriss R, Arthur A, Sach T, Hippisley-Cox J,. A study of the safety and harms of antidepressant drugs for older people: A cohort study using a large primary care database. Health Technol Assess 2011; 15: 5-218.
33. Hien LTT, Cumming RG, Cameron ID, Chen JS, Lord SR, March LM, Schwarz J, Le Couteur DG, Sambrook PN,. Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J Am Geriatr Soc 2005; 53: 1290-95.
34. Thapa PB, Gideon P, Cost TW, Milam AB, Ray WA,. Antidepressants and the risk of falls among nursing home residents. New England J Med 1998; 339: 875-82.
35. Carriere I, Fourrier-Reglat A, Dartigues JF, Rouaud O, Pasquier F, Ritchie K, Ancelin ML,. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: The 3-city study. Arch Intern Med 2009; 169: 1317-24.
36. Whalley LJ, Sharma S, Fox HC, Murray AD, Staff RT, Duthie AC, Deary IJ, Starr JM,. Anticholinergic drugs in late life: Adverse effects on cognition but not on progress to dementia. J Alzheimers Dis 2012; 30: 253-61.
37. Luukkanen MJ, Uusvaara J, Laurila JV, Strandberg TE, Raivio MM, Tilvis RS, Pitkala KH,. Anticholinergic drugs and their effects on delirium and mortality in the elderly. Dement Geriatr Cogn Disord Extra 2011; 1: 43-50.
38. Panula J, Puustinen J, Jaatinen P, Vahlberg T, Aarnio P, Kivela SL,. Effects of potent anticholinergics, sedatives and antipsychotics on postoperative mortality in elderly patients with hip fracture: A retrospective, population-based study. Drugs Aging 2009; 26: 963-71.
39. Uusvaara J, Pitkala KH, Kautiainen H, Tilvis RS, Strandberg TE,. Association of Anticholinergic Drugs with Hospitalization and Mortality among Older Cardiovascular Patients A Prospective Study. Drugs Aging 2011; 28: 131-38.
40. Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, Coulton S, Katona C, Boustani MA, Brayne C,. Anticholinergic Medication Use and Cognitive Impairment in the Older Population: The Medical Research Council Cognitive Function and Ageing Study. J Am Geriatr Soc 2011; 59: 1477-83.
41. Mangoni AA, van Munster BC, Woodman RJ, de Rooij SE,. Measures of anticholinergic drug exposure, serum anticholinergic activity, and all-cause postdischarge mortality in older hospitalized patients with hip fractures. Am J Geriat Psychiatry: Official J Am Assoc Geriatric Psych 2013; 21: 785-93.
42. Fox C, Smith T, Maidment I, Chan WY, Bua N, Myint PK, Boustani M, Kwok CS, Glover M, Koopmans I, Campbell N,. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing 2014; 43: 604-15.
43. Schneider LS, Dagerman K, Insel PS,. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatric Psych 2006; 14: 191-210.
44. Tannenbaum C, Paquette A, Hilmer S, Holroyd-Leduc J, Carnahan R,. A Systematic Review of Amnestic and Non-Amnestic Mild Cognitive Impairment Induced by Anticholinergic, Antihistamine, GABAergic and Opioid Drugs. Drugs Aging 2012; 29: 639-58.
45. Gillis A, MacDonald B,. Deconditioning in the hospitalized elderly. Canadian Nurse J 2005; 101: 16-20.
46. Barr RG, Bourbeau J, Camargo CA, Ram FS,. Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax 2006; 61: 854-62.
47. Oba Y, Zaza T, Thameem DM,. Safety, tolerability and risk benefit analysis of tiotropium in COPD. Int J Chron Obstruct Pulmon Dis 2008; 3: 575-84.
48. Salpeter SR, Buckley NS,. Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. Clin Rev Allergy Immunol 2006; 31: 219-30.
49. Singh S, Loke YK, Furberg CD,. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300: 1439-50.
50. Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS,. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013; 68: 48-56.
51. Singh S, Loke YK, Enright PL, Furberg CD,. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011; 342: d3215.
52. Roughead EE, Semple SJ,. Medication safety in acute care in Australia: where are we now? Part 1: a review of the extent and causes of medication problems 2002-2008. Aust New Zeal Health Pol 2009; 6: 18.
53. Lucado J, Paez K, Elixhauser A,. Medication-Related Adverse Outcomes in U.S. Hospitals and Emergency Departments. In, Agency for Healthcare Research and Quality, 2008.
54. AIHW. Hospitalisations due to falls by older people, Australia: 2009-10. In, edAIHW, Canberra: Australian Institute of Health and Welfare, 2013.
55. CDCP. Costs of Falls Among Older Adults. In: Centers for Disease Control and Prevention, 2014.
56. Kennedy JS, Bymaster FP, Schuh L, Calligaro DO, Nomikos G, Felder CC, Bernauer M, Kinon BJ, Baker RW, Hay D, Roth HJ, Dossenbach M, Kaiser C, Beasley CM, Holcombe JH, Effron MB, Breier A,. A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. Int J Geriatr Psychiatry 2001; 16 (Suppl 1): S33-61.
57. Mangoni AA, Jackson SH,. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004; 57: 6-14.
58. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D,. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
59. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions In: The Cochrane Collaboration, 2011.